Medtech company Onkos Surgical received 510(k) clearance from the FDA for its antibacterial-coated orthopedic implants.
Onkos Surgical’s ELEOS Proximal Tibia with NanoCept Antibacterial Technology prevents intraoperative bacterial contamination during orthopedic implant procedures, according to an Oct. 21 news release from the company.
In preclinical studies, the technology had a 99.999% kill rate of bacteria that are commonly found in operating room environments.
The implants earned the FDA’s De Novo approval in April 2024.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
